An extended access program to assess long-term safety of bardoxolone methyl in patients with pulmonary hypertension

This is a Phase 3a, extended access program to assess long-term safety of bardoxolone methyl in patients with pulmonary hypertension. The purpose of this study is to provide or continue to provide bardoxolone methyl to eligible subjects who participated in the CATALYST study. The study will also collect ongoing safety and tolerability data of bardoxolone methyl.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Pulmonary Hypertension
• Age: - 99 Years
• Gender: All